Table 1.
Baseline demographic and clinical characteristics of the enrolled patients just before the introduction of sorafenib.
| Variables | All (n = 61) | Male (n = 53) | Female (n = 8) | p-Value |
|---|---|---|---|---|
| Age (years) | 67.3 ± 11.5 | 68.9 ± 10.0 | 59.8 ± 12.4 | 0.022 |
| Etiology (HBV/HCV/others) | 13/28/20 | 9/27/17 | 4/1/3 | 0.042 |
| Child–Pugh score (5/6) | 43/18 | 39/14 | 3/5 | 0.094 |
| Cancer stage (III/IVA/IVB) | 20/13/28 | 16/13/24 | 4/0/4 | 0.262 |
| BMI (kg/m2) | 22.3 ± 3.0 | 22.1 ± 2.7 | 23.5 ± 4.7 | 0.218 |
| Extrahepatic metastasis (lung/bone/others) | 16/9/9 | 14/8/8 | 2/1/1 | 1.000 |
| SMI (cm2/m2) | 43.7 ± 7.4 | 44.2 ± 7.3 | 39.8 ± 6.8 | 0.118 |
| SATI (cm2/m2) | 34.9 ± 22.0 | 30.5 ± 17.7 | 64.2 ± 26.6 | <0.001 |
| VATI (cm2/m2) | 36.6 ± 20.9 | 37.4 ± 21.5 | 31.8 ± 16.8 | 0.485 |
| Therapeutic effect (CR/PR/SD/PD) | 3/5/19/34 | 3/3/16/31 | 0/2/3/3 | 0.203 |
| Sarcopenia (yes/no) | 25/36 | 22/31 | 3/5 | 1.000 |
| Median duration of sorafenib treatment (months) | 15.7 (12.3–19.0) | 13.3 (12.2–19.5) | 9.8 (6.3–22.3) | 0.754 |
| Median survival time after introducing sorafenib (months) | 19.8 (5.1–26.1) | 17.7 (5.5–35.6) | 15.8 (7.7–30.3) | 0.803 |
Values are presented as mean ± standard deviation. Sarcopenia was defined as an SMI value of ≤38.0 cm2/m2 for women and ≤42.0 cm2/m2 for men. HBV, hepatitis B virus; HCV, hepatitis C virus; BMI, body mass index; SMI, skeletal muscle index; SATI, subcutaneous adipose tissue index; VATI, visceral adipose tissue index; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease.